A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma

Thrombosis and Haemostasis

Volumn 98, Issue 4, 2007, Pages 871-882

  He, Shu ^a,b   Zhu, Kun ^a   Skeppholm, Mika ^a   Vedin, Jenny ^a   Svensson, Jan ^a   Egberg, Nils ^a   Blombäck, Margareta ^a   Wallen, Hakan ^a  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anticoagulation; Global assay; Haemostasis balance; Hypercoagulability; Reaction rate determination

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; FIBRIN; HEPARIN; PHOSPHOLIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT THROMBOPLASTIN; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BIOASSAY; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPUTER PROGRAM; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; FIBRIN FORMATION; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; THROMBOCYTE POOR PLASMA; THROMBOPHILIA; TURBIDITY;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION; FIBRIN; FIBRINOLYSIS; HEMOSTASIS; HUMANS; MIDDLE AGED; PHOSPHOLIPIDS; RECOMBINANT PROTEINS; SOFTWARE; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 35048822823     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-07-0370     Document Type: Article

References (21)

1. Lawson JH, Kalafatis M, Stram S, et al. A model for the tissue factor pathway to thrombin I. An empirical study. J Biol Chem 1994; 269: 23357-23366.
2. Downey C, Kazmi R, Toh CH. Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation. Br J Haematol 1997; 98: 69-73.
3. Hemker HC, Giesen P, AlDieri R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-253.
4. Smith AA, Jacobson L J, Miller B I, et al. A new euglobulin clot lysis assay for global fibrinolysis. Thromb Res 2003; 112: 329-337.
5. Sorensen B, Johansen P, Christiansen K, et al. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 1: 551-558.
6. He S, Antovic A, Blombäck M. A simple and rapid laboratory method for determination of haemostasis potential in plasma - II. Modifications for use in routine laboratories and research work. Thromb Res 2001; 103: 355-361.
7. Antovic A, Blomback M, Sten-Linder M, et al. Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma. Blood Coagul Fibrinolysis 2005; 16: 585-596.
8. Schneider M, Nesheim M. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis. J Thromb Haemost 2003; 1: 147-154.
9. Li N, He S, Blomback M, et al. Platelet activity, coagaulation, and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaparin. Arterioscler Thromb Vasc Biol 2007; 27: 407-413.
10. Eriksson BI, Arfwidsson AC, Frison L, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. Thromb Haemost 2002; 87: 231-237.
11. Ersdal E, Schutzer K, Lonnerstedt C, et al. Plasma concentration of melagatran after ingestion of different doses of the drug. Clin Drug Invest 2005; 25: 125-133.
12. He S, Cao, H, Antovic A, et al. Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials. Blood Coagul Fibrinolysis 2005; 16: 61-67.
13. Collet JP, Park D, Lesty C, et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vase Biol 2000; 20: 1354-1361.
14. Collet JP, Soria J, Mirshahi M, et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood 1993; 82: 2462-2469.
15. Hoffman M, Monroe DM. A cell-based model of hemostasis.Thromb Haemost 2001; 85: 958-965.
16. Tebbe U, Seifried E, Carlsson J, et al. Thrombolysis using consecutive high dose bolus and inflision of alteplase in a patient with acute massive pulmonary embolism. Blood Coagul Fibrinolysis 1992; 3: 475-480.
17. Verstraete M. In: Thrombolysis in Cardiovascular Disease, New York and Basel: Marcel Dekker, 1989: 69-86.
18. Kaufman RJ, Antonarakis SE, Fay PJ. Factor VIII and hemophilia A. In: Textbook of Haemostasis and Thrombosis, Basic principles and clinical practice. 4th ed. Lippincott, Willams & Wilkins 2000: 135-156.
19. Franchini M, Veneri D. Inherited thrombophilia: an update. Clin Lab 2005; 51: 357-365.
20. Nordt TK, Peter K, Ruef J, et al. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost 1999; 82: 14-18.
21. Willams S, Fatah K, Ivert T, et al. The effect of acetylsalicylic acid on fibrin gel lysis by tissue plasminogen activator. Blood Coagul Fibrinolysis 1995; 6: 718-725.